EPO has just recently published a new study on molecular characterization and chemosensitivity testing of its established glioblastoma (GBM) PDX model panel in the journal Frontiers Oncology. Highlights of this study include:

• A panel of 26 patient-derived subcutaneous xenograft (PDX) GBM models was established and screened in immunodeficient mice, providing a valuable platform for studying GBM biology.
  
• Sensitivity to a drug panel with different modes of action was determined, revealing the best treatment responses for temozolomide (standard of care), irinotecan, and bevacizumab.
  
• Intracranial models, which mimic the tumor microenvironment in the brain, showed reduced drug sensitivity due to the blood-brain barrier limiting drug penetration to the tumor.

These findings provide significant insights into the heterogenous and complex biology of GBMs and offer a promising avenue for developing targeted therapies. Further research on molecular markers and drug optimization using this platform can pave the way for improved treatment options for GBM patients.

Read study